SLC5A2 and type 2 diabetes mellitus: Experimental studies have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have diverse effects including modulation of the RAS as well as attenuating systemic inflammation and oxidative stress, which has been previously associated with cardiorenal protection in patients with type 2 diabetes mellitus (147).